

Department of Radiation Oncology

Monthly Research Update: July 2022

Preparing for NIH Data Sharing

NIH-funded researchers and those preparing submissions should be aware of the January 25 implementation date for the new [NIH Data Management and Sharing \(DMS\) Policy](#). As summarized in a recent review of assistance resources for implementation, the central tenets of the policy are that: (1) investigators and institutions must prospectively plan for managing and appropriately sharing data by developing a Data Management and Sharing Plan (“DMS Plan”); and (2) they must follow through with this plan. The goal of the policy is to ensure that investigators have data management and plans in place before research is underway. To aid researchers in establishing plans, NIH released an optional [DMS Plan format page](#), intended to guide investigators through the [Elements of a DMS Plan](#). A preview version of this format page is available now as a reference. A final, fillable version, along with detailed instructions for preparing DMS Plans, will be incorporated into the FORMS-H NIH Application Instructions, available in the fall. To reduce burdens on investigators also subject to the Genomic Data Sharing (GDS) Policy, NIH will no longer require submission of separate GDS Plans.

DMS Plans will be reviewed and assessed by NIH program staff, not by peer reviewers. Plans will not factor into Overall Impact scores; however, peer reviewers may comment on the reasonableness of proposed data management and sharing costs based on information in the budget justification. NIH staff will determine whether DMS Plan elements are reasonably addressed, and applications will be funded only if plans are acceptable. The [NIH Scientific Data Sharing website](#) provides real-time updates on late changes, resources, and other policy information.

Clinical Trial Enrollment

- 20 patients were enrolled at MPTC on the **PCG Registry**.
- 1 patient was enrolled on the **Deep Thermal Therapy HUD**.
- 1 patient was enrolled at UCH and 4 at MPTC on **GCC 20110**: A single-arm, single-stage phase II trial of Selective Avoidance of nodal VolumEs at minimal Risk (SAVER) in the contralateral neck of patients with p16-positive oropharynx cancer.
- 5 patients were enrolled at MPTC on **GCC 19146**: Comparison and verification of radiation planning for pencil beam scanning proton therapy using single energy and dual energy computed tomography simulation methods.
- 1 patient was enrolled at UMMC on **RTOG 1308**: Phase III randomized trial comparing overall survival after photon versus proton chemoradiotherapy for inoperable stage II-IIIb NSCLC.
- 1 patient was enrolled at MPTC on **GCC15100**: Pragmatic phase III randomized trial of proton vs. photon therapy for patients with non-metastatic breast cancer receiving comprehensive nodal radiation: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial.
- 1 patient was enrolled at MPTC on **NRG HN009**: Randomized phase II/III trial of radiation with high-dose cisplatin (100 mg/m²) every three weeks versus radiation with low-dose weekly cisplatin (40 mg/m²) for patients with locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN).
- 1 patient was enrolled at UMMC on **GCC 1876**: Tumor bed boost using a breast specific radiosurgery device, the GammaPod: Registry study and evaluation of quality of life with development of sizing nomogram.
- 1 patient was enrolled at UMMC on **EAF151**: Change in relative cerebral blood volume as a biomarker for early response to bevacizumab in patients with recurrent glioblastoma.

JULY AT A GLANCE TOTALS

Clinical trials

Total enrolled	36
GCC, other	13
NRG, NCI, co-ops	3
PCG Registry	20

Grants and contracts

New awards	2
Submitted	2

Articles published

5

Information for this monthly update should be provided no later than the second Wednesday of each month to Miek Segers at msegers@som.umaryland.edu. The update will be published on the second Friday of each month.

Have questions about identifying a funding source? Finding research partners across the UMB/UM campuses or at another university? Defining future research strategies? Or organizing your thoughts on (virtual) paper? Contact Nancy Knight, PhD, Director of Academic and Professional Development for the department, at nknight@umm.edu

Grants and Contracts

Funded:

- **Dario Rodrigues, PhD, and Jason Molitoris, MD, PhD**, PIs, for a Sensius B.V. consultancy agreement for “Image-guided hyperthermia for the treatment of tumors” (March 2022–May 2024; \$17,049).
- **Byongyong Yi, PhD, PI**, from Varian Medical Systems, Inc., for “Non-clinical evaluation of the treatment time calculation flow” (May–October 2022; \$20,000).

Submitted:

- **Hem Shukla, PhD, PI**, Department of Defense Lung Cancer Research Program for “Caveolin-1 as a clinical prognostic biomarker for radiation resistance and tumor aggression in lung cancer” (July 2023–June 2026; \$926,935).
- **Phuoc T. Tran, MD/PhD, PI**, Collaboration/subagreement with the University of Wisconsin (prime applicant) on NIH R01 for “Tumor barcoding and high-throughput sequencing to assess genomic predictors of TYRT response and immunomodulation in NSCLC” (April 2023–March 2028; \$1,282,350).

Articles Published

Entered into PubMed July 7–August 10. Titles link to PubMed abstracts, where full-text links are available.

1. **Kalavagunta C, Xu H, Zhang B, Mossahebi S, MacFarlane M, Jiang K, Lee SW, Chen S, Sawant A, Gopal A, Yi B.** [Is a weekly qualitative picket fence test sufficient? A proposed alternate EPID-based weekly MLC QA program.](#) *J Appl Clin Med Phys.* 2022;23(8):e13699.
2. Kernagis DN, **Balcer-Kubiczek E, Bazyar S**, Orschell CM, Jackson IL. [Medical countermeasures for the hematopoietic subsyndrome of acute radiation syndrome in space.](#) *Life Sci Space Res.* 2022 June 9. Online ahead of print.
3. Smith KC, White S, DeSanto J, Hannum S, Mayonado N, Ahuja N, Bowie J, Cowall D, Mischtschuk J, Peairs K, Thorner E, **Tran P**, Wolff A, Snyder C. [Implementing survivorship care planning in two contrasting health systems: Lessons learned from a randomized controlled trial.](#) *J Cancer Surviv.* 2022;16(4):791–800.
4. Wang S, Ryan Russell J, Drescher M, Park A, Legesse T, Kundra V, **Tran PT**, Phelan M, Naslund M, Minhaj Siddiqui M. [Prostate cancer grade downgrading at time of prostatectomy provides risk-stratification insight into future tumor behavior after prostatectomy.](#) *Prostate.* 2022 Aug 3. Online ahead of print.
5. **Yao W, Zhang B, Han D, Polf J, Vedam S, Lasio G, Yi B.** [Use of CBCT plus plan robustness for reducing QACT frequency in intensity-modulated proton therapy: Head-and-neck cases.](#) *Med Phys.* 2022 Aug 6. Online ahead of print.

Important Dates for Upcoming Funding Submissions

Below is an updated calendar with firm due dates for upcoming major NIH deadlines (individual RFA/PA dates may differ). Contact the Department Office of Research Administration (DORA) (msegers@som.umaryland.edu) ASAP if you plan to submit any funding proposal, regardless of funder. Failure to meet these deadlines may result in delaying your submission until the next cycle (if available).

NIH deadline	DORA budget, prelim materials	Dean/SOM prelim materials	FINAL Dean/SOM/SPA
R01 new 10/05/22	09/21/22	09/26/22	09/28/22
R21 new 10/16/22	10/03/22	10/06/22	10/10/22
R01 resub 11/05/22	10/24/22	10/27/22	10/31/22
R21 resub 11/16/22	11/02/22	11/07/22	11/09/22

*Note: If you are preparing an NIH submission of another type for September, you should be aware that Grants.gov will migrate their services to the cloud during an extended downtime from September 23 through September 29. To mitigate the impact, NIH due dates that fall on or between Thursday, September 22, and Friday, September 30, will move to October 3. More details, including caveats and considerations, are available on the [Grants.gov migration information page](#). **Please contact the Department Office of Research Administration ASAP if you plan to file in this time period.**